Feb 13, 2020 7:00am EST Can-Fite Submits Liver Cancer Phase III Protocol and Registration Plan to EMA for Namodenoson
Feb 03, 2020 7:30am EST Can-Fite Completes 50% Patient Enrollment in Phase III Rheumatoid Arthritis Study & Implements Interim Analysis
Jan 16, 2020 7:00am EST Can-Fite and Univo Pharmaceuticals Collaboration Result in Discovery and Applied Patent for Cannabinoid Formulations with Broad Therapeutic Effects
Jan 07, 2020 8:20am EST Data from the Phase II Liver Cancer Study with Namodenoson will be presented at the ISCORT Conference by Dr. Stemmer
Jan 03, 2020 7:00am EST New Data From Hadassah Medical Center Lab Show Can-Fite’s Namodenoson Induces Weight Loss
Dec 26, 2019 7:00am EST Golan Bitton Univo Pharmaceutical CEO Elected to the Can-Fite Board: A Strategic Partnership with Univo to Develop Cannabinoid-Based Products is Ongoing
